Abstracts tagged "systemic lupus erythematosus (SLE) and thrombosis"

Abstract Number: 2553 • 2013 ACR/ARHP Annual Meeting
The Clinical Value Of Testing For Aphl, a New ELISA Kit With a Unique Phospholipid Mixture In Patients With Systemic Lupus Erythematosus (SLE)
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antibodies directed to APhL (a mixture of phospholipids) have been reported to predict APS more reliably than aCL tests. We designed this study to…
Abstract Number: 2516 • 2013 ACR/ARHP Annual Meeting
Plasma Microparticles Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Michelle Petri¹, Melissa Nastacio², Hong Fang¹, Thomas Kickler¹, Jayesh Jani¹ and Laurence S. Magder³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Thrombosis in SLE is highly associated with antiphospholipid antibodies, yet the majority of those with antiphospholipid antibodies never have a thrombotic event. Plasma microparticles…
Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Savino Sciascia¹, Mª Jose Cuadrado², Giovanni Sanna³, Veronica Murru⁴, Dario Roccatello¹, Oier Ateka⁵, Munther A. Khamashta⁶ and Maria Laura Bertolaccini⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Lupus Research Unit, The Rayne Institute, London, United Kingdom, ³Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Unit, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…
Abstract Number: 16 • 2013 ACR/ARHP Annual Meeting
Only IgG and IgA β₂glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Anne Tebo^1,2, Rohan Willis³, Troy Jaskowski¹, Laurence S. Magder⁴, Silvia S. Pierangeli³, Ware Branch⁵ and Michelle Petri⁶, ¹ARUP Laboratories, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The current APS Classification Criteria recommend testing for IgG and IgM antibodies for β2glycoprotein I (β2GPI), and do not differentiate between primary and secondary…
Abstract Number: 2569 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
Genevieve Law¹, Laurence S. Magder², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Past studies, mostly cross-sectional, have found a reduction in thrombosis in systemic lupus erythematosus (SLE) patients taking hydroxychloroquine (HCQ). We examined the relationship between…
Abstract Number: 1740 • 2012 ACR/ARHP Annual Meeting
Impairment of Quality of Life in Patients with Antiphospholipid Syndrome
Stephane Zuily¹, Francis Guillemin², Veronique Regnault³, Pierre Kaminsky⁴, Patrick Mismetti⁵, Jacques Ninet⁶, Nicolas Baillet⁷, Nadine Magy-Bertrand⁸, Bernard Lorcerie⁹, Jean-Louis Pasquali¹⁰, Thomas Lecompte¹¹, Anne-Christine Rat¹² and Denis Wahl¹³, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, Orphan disease Unit, Nancy, France, ⁵CHU Saint-Etienne, Unité de Pharmacologie Clinique, Groupe de Recherche sur la Thrombose (EA 3065), Saint Etienne, France, ⁶Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁷Hôpitaux civils de Colmar, Service de Médecine interne, Colmar, France, ⁸CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁹Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁰Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ¹¹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹²Université de Lorraine, INSERM, CIC-EC CIE6, Rheumatology, Epidemiology, Nancy, France, ¹³Nancy University Hospital and INSERM U961, Vascular medicine division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France
Background/Purpose : Quality of life (QoL) is an important outcome in clinical care especially in patients with chronic disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting
Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Nathalie Bardin³, Marielle San Marco³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Hopital de la Conception, Marseille, France
Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…
Abstract Number: 1732 • 2012 ACR/ARHP Annual Meeting
Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Xiao Xuan Wu³, Jacob Rand⁴ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, NY
Background/Purpose: Annexins are a family of structurally related proteins that bind to phospholipids in a calcium dependant manner. Annexin A5 (AnxA5), present on the surfaces…
Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Savino Sciascia¹, Veronica Murru¹, Giovanni Sanna², Dario Roccatello³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini¹, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Renata Baronaite Hansen¹ and Søren Jacobsen², ¹Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
Abstract Number: 1423 • 2012 ACR/ARHP Annual Meeting
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Amir Haddad¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The trigger for a thrombotic in patients with antiphospholipid antibodies is unknown. Thrombocytopenia is among the most common clinical manifestations of the Antiphospholipid antibody…
Abstract Number: 1425 • 2012 ACR/ARHP Annual Meeting
Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Gregg J. Silverman¹, John Jung², Ehtisham Akhter³, Michelle Petri⁴ and Caroline Grönwall², ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: SLE patients are at risk for diverse organ systems involvement, which increases the challenges for diagnosis and predictions for the development of specific clinical…
Abstract Number: 1396 • 2012 ACR/ARHP Annual Meeting
Associates of a History of Thrombosis in Systemic Lupus Erythematosus
Melissa Nastacio¹, Hong Fang², Thomas Kickler², Jayesh Jani², Laurence S. Magder³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Thrombosis in SLE is highly associated with antiphospholipid antibodies, yet the majority of those with antiphospholipid antibodies never have a thrombotic event. Plasma microparticles…
Abstract Number: 662 • 2012 ACR/ARHP Annual Meeting
Increased C1q, C4 and C3 Deposition On Platelets in Patients with Systemic Lupus Erythematosus – A Possible Link to Venous Thrombosis?
Christian Lood¹, Sam Eriksson¹, Birgitta Gullstrand², Andreas Jönsen¹, Gunnar Sturfelt³, Lennart Truedsson² and Anders A. Bengtsson⁴, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing vascular diseases (VD) such as myocardial infarction, stroke and venous thrombosis, which…
Abstract Number: 643 • 2012 ACR/ARHP Annual Meeting
Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura
Yeon-Ah Lee¹, Somi Kim¹, Ran Song² and Sang-Hoon Lee², ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ²Rheumatology, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic inflammatory autoimmune disease capable of exhibiting virtually any clinical symptoms, occasionally presents itself with thrombocytopenic purpura as an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].